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ABSTRACT 
Hydroxychloroquine (HCQ) is an antimalarial medication that can also be used to treat autoimmune diseases. However, 
it can produce irreversible changes to the retina that lead to visual impairment. The aim of this study was to determine 
the proportion of patients treated with HCQ who develop retinal toxicity and the risk factors for the development of 
HCQ-induced retinal toxicity among Iranian patients. The is a cross-sectional clinical study of 59 patients who were 
treated with HCQ during 2014–2015. A questionnaire was used to collect data on the following demographic and clinical 
factors: age, gender, type of rheumatic disease, history of cataract surgery, daily and cumulative HCQ dose, and duration 
of HCQ use. Retinal toxicity was diagnosed on the basis of the automated perimetry results of the central 10° of vision 
and spectral domain optical coherence tomography. The associations between the demographic and clinical factors and 
retinal toxicity were assessed, and P < 0.05 was considered statistically significant. Retinal toxicity was detected in 18 
(30.5%) of the patients, and 5 (8.5 %) developed color vision impairments. There was no association between retinal 
toxicity and sex (P = 0.514), history of cataract surgery (P = 0.479), type of rheumatic disease (P = 0.539), or daily HCQ 
dose (P = 0.062). However, there was a significant positive association between retinal toxicity and age (P = 0.006), 
cumulative HCQ dose (P = 0.002), and duration of HCQ use (P < 0.001). In conclusion, the risk factors for retinal toxicity 
after HCQ treatment were advanced age, use of a higher cumulative HCQ dose, and a longer duration of treatment. 
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Hydroxychloroquine (HCQ) has been used for many years 
to reduce inflammation in the treatment of patients with 
multiple rheumatologic diseases, including systemic 
lupus erythematosus (SLE) and rheumatoid arthritis (RA) 
(1). Antimalarial medications (HCQ and chloroquine) are 
among the safest antirheumatic medications as they are 
rarely associated with side effects (2). The most common 
adverse effects are related to the gastrointestinal tract, 
skin, and nervous system (3). 
However, one of the most serious side effects is ocular 
toxicity, which has been found to be more common 
when HCQ is used for long periods of time (4). Therefore, 
there is considerable concern about the risk of ocular 
problems among patients treated with HCQ, and regular 
screening (in accordance with standard guidelines) is 
necessary, even in the absence of ocular symptoms (5). 
HCQ-induced ocular toxicity can occur in two distinct 
areas of the eye: the cornea and the macula (5). 
The changes in the macula can potentially be serious, as 
the consequences can include loss of vision. The 
mechanism by which antimalarial medications cause 
retinal toxicity involves the binding of the drugs to the 
melanin in the pigmented epithelial layer of the retina, 
and subsequent damage to rods and cones (6). Retinal 
toxicity had been classically characterized as involving 
bilateral “bull’s-eye” maculopathy, initial photoreceptor 
damage with a parafoveal distribution, and further 
damage with a more peripheral extramacular distribution 
(5). 
The risk of developing retinal toxicity has been found to 
be dependent on the daily HCQ dose and the duration of 
use. The risk of retinal toxicity is <1% for those who use 
HCQ for up to 5 years and <2% for those who use HCQ 
for 5–10 years, but it rises to almost 20% after 20 years 
of HCQ use (5). Other major risk factors include having a 
concomitant renal disease and the concomitant use of 
certain medications such as tamoxifen (5). The findings of 
previous studies regarding the degree of risk of HCQ-
induced retinopathy are conflicting (7). 
Furthermore, although HCQ is frequently used in 
rheumatology, there are limited studies on the clinico-
epidemiological characteristics of retinal toxicity in 
Iranian patients treated with HCQ (8, 9). Therefore, the 
aims of this study were to evaluate the percentage of 
Iranian patients taking HCQ who develop retinal toxicity 
and to identify the associated risk factors. 
MATERIALS AND METHODS 
The protocol for this study was approved by the 
Institutional Ethics Committee of Semnan University of 
Medical Sciences, Semnan, Iran (project No. 584582). 
Following the approval of the institutional review board, 
we identified the medical reports of patients who were 
treated with HCQ between September 2014 and 
September 2015, and these patients were referred to an 
expert ophthalmologist at Semnan University of Medical 
Sciences. 
The inclusion criteria included age ≥ 17 years and use of 
HCQ from September 2014 to September 2015 (along 
with any past use). We excluded patients if they had a 
clinically significant chronic ocular problem (including 
diabetic retinopathy) or if they were taking a medication 
other than HCQ with retinotoxic side effects. All 59 
subjects who met the inclusion and exclusion criteria 
signed the informed consent forms to take part in the 
study. A questionnaire was used to collect patient data. 
The first section of the questionnaire collected data on 
basic demographic and clinical characteristics (age, sex, 
and type of rheumatic disease), and the second section 
collected data on the patients’ ophthalmologic history 
(history of cataract surgery, daily and cumulative HCQ 
dose, and duration of HCQ use). The rheumatic diseases 
were divided in to three groups: SLE, RA, or others. 
Subsequently, ophthalmologic assessments were carried 
out for each subject. These assessments included visual 
acuity (VA) tests of both eyes using a Snellen chart at 6 
m, a biomicroscopic examination of the fundus under 
dilation, a fundus examination using indirect 
ophthalmoscopy, a color vision exam, visual field testing 
of the central 10° using automated perimetry with a 
Swedish Interactive Threshold Algorithm (SITA)-Standard 
strategy, and spectral domain optical coherence 
tomography. The results of all the examinations were 
interpreted by the same ophthalmologist. 
In accordance with the 2011 recommendations of the 
American Academy of Ophthalmology, which state that 
retinal toxicity should be diagnosed on the basis of 
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alterations in at least two tests, retinal toxicity was 
diagnosed on the basis of the automated perimetry 
results of the central 10° and spectral domain optical 
coherence tomography (5). Although multiple methods 
have been suggested for retinal toxicity screening among 
patients treated with HCQ, there is no acceptable “gold 
standard” for the identification of HCQ-induced retinal 
toxicity before the onset of decreased vision (10-12). 
The data were analyzed using Statistical Package for 
Social Sciences (SPSS) version 16 (SPSS Inc., Chicago, IL, 
USA). The data are described using frequencies, 
percentages, means, medians, ranges, and standard 
deviations. We used t-tests for numerical variables and 
chi-square tests for categorical variables to determine 
the association between retinal toxicity and sex, history 
of cataract surgery, type of rheumatic disease, daily HCQ 
dose, cumulative HCQ dose, and duration of HCQ use. P < 
0.05 was considered statistically significant. Disease 
characteristics were compared between the two groups 
using chi-square for categorical variables, Mann-Whitney 
U test for nonparametric ordinal variables and student t 
test for parametric variables. 
The changes from the baseline to the end of study period 
within each group were tested using Wilcoxon Signed 
Rank test for nonparametric variables and paired t test 
for parametric variables. 
RESULTS 
The baseline characteristics of the patients are 
summarized in Table 1. Among the 59 included patients, 
54 (91.5%) were women. They were aged 16–83 years 
(mean ± SD: 42.3±12.3 years). The mean duration of HCQ 
use ± SD was 44.5 ± 35.9 months, and the median 
duration was 36 months (Table 1). 
The funduscopic, spectral domain optical coherence 
tomography and perimetry results showed that 18 
(30.5%) of the patients had retinal toxicity. The patients 
with abnormal funduscopic values all had abnormal 
perimetry values. Five (8.5%) patients had abnormal 
color vision. 
 
Table 1. Baseline Characteristics of Patients 
a, b
 
Characteristic Value 
Sex  
Men 5 (8.5) 
Women 54 (91.5) 
Age, Y  
Mean ± SD 42.3 ± 12.3 
Range 16-83 
Median 40 
Type of Rheumatic Disease  
Rheumatoid Arthritis 36 (61) 
Systemic Lupus Erythematosus 16 (27.1) 
Other 7 (11.9) 
History of Cataract Surgery  
Cataract Surgery 2 (3.4) 
None 57 (96.6) 
Duration of HCQ Use  
Mean ± SD 44.5 ± 35.9 
Median 36 
a
 Abbreviations: HCQ, hydroxychloroquine. 
b
 Data are presented as No. (%) or Mean ± SD. 
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Seventeen women (31.5%) and one man (20%) had 
retinal toxicity, and there was no association between 
sex and retinal toxicity (P = 0.514). The mean age ± SD of 
patients with and without retinal toxicity was 45.8 ± 7.7 
and 40.9 ± 13.2 years, respectively. There was a 
significant difference between patients aged <40 and ≥40 
years in retinal toxicity (P = 0.006), with 14 (46.7%) of 
those aged ≥40 years and only four (13.8%) of those aged 
<40 years having retinal toxicity (Table 2). 
Neither prior cataract surgery nor the type of rheumatic 
disease was associated with retinal toxicity (P = 0.479 
and P = 0.539, respectively). The prevalence of retinal 
toxicity was 36.2% among patients who used ≤200 mg 
HCQ per day and 8.3% among those who used >200 mg 
HCQ per day, and there was no significant association 
between daily HCQ dose and retinal toxicity (P = 0.062). 
Regarding the cumulative HCQ dose, 7.4% of patients 
who used ≤100 g of HCQ had retinal toxicity and 52.2% of 
those who used >200 g had retinal toxicity (Table 2), and 
the cumulative HCQ dose was significantly associated 
with retinal toxicity (P = 0.002). The mean duration of 
HCQ use ± SD among patients with retinal toxicity was 
significantly larger than that among those without retinal 
toxicity (P < 0.001) at 75.2 ± 45.1 months and 29.3 ± 21.5 
months, respectively (Table 2). 
 
 
Table 2. Frequency of Retinal Toxicity in Different Groups 
Variable 
Retinal Toxicity 
P Value 
No Yes 
Sex   0.514 
Men  4 (80) 1 (20)  
Women  38 (68.5) 17 (31.5)  
Age, Y   0.006 
<40 25 (86.2) 4 (13.8)  
≥40 16 (53.3) 14 (46.7)  
Type of Rheumatic Disease   0.539 
Rheumatoid Arthritis 25 (69.4) 11 (30.6)  
Systemic Lupus Erythematosus 10 (62.5) 6 (37.5)  
Other 6 (85.7) 1 (14.3)  
Daily HCQ Dose, mg   0.062 
<200 30 (63.8) 17 (36.2)  
≥200 11 (91.7) 1 (8.3)  
Cumulative HCQ Dose, mg   0.002 
<100 25 (92.6) 2 (7.4)  
100-199 5 (55.6) 4 (44.4)  
≥200 11 (47.8) 12 (52.2)  
Duration of HCQ Use, mo 29.3 ± 21.5 75.2 ± 45.1 < 0.001 
a
 Abbreviations: HCQ, hydroxychloroquine. 
b
 Data are presented as No. (%) or Mean ± SD. 
 
DISCUSSION
Our study showed that approximately 30% of the 
patients treated with HCQ had retinal toxicity. There was 
no association between retinal toxicity and sex, type of 
rheumatic disease, and daily HCQ dose. However, there 
was a positive correlation between retinal toxicity and 
age, cumulative HCQ dose, and duration of HCQ use. 
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HCQ is an important medication that is very effective for 
treating SLE and other rheumatic conditions. It is 
generally well tolerated, and its side effect profile is 
superior to those of many other immunosuppressive 
medications (1). However, a major concern regarding this 
drug is the increased risk of developing irreversible 
retinopathy. Unfortunately, these retinopathies usually 
present insidiously (1). 
Therefore, evaluations of percentages of people who 
take HCQ and develop retinal toxicity, and the associated 
risk factors, are important. The exact incidence and 
prevalence of HCQ-induced retinal toxicity is unknown. 
As the incidence and prevalence data on collagen 
vascular disorders (such as SLE and RA) are variable, it is 
difficult to calculate the exact risk of retinal toxicity 
among patients with RA and SLE who are treated with 
HCQ (13). However, the relative prevalence of retinal 
toxicity among those who use antimalarial medications 
(HCQ and chloroquine) is approximately 0.025: 100,000 
(14, 15). 
A registry-based study of 3,995 patients with RA or SLE 
who used HCQ showed that the risk of retinal toxicity 
was low during the first 5–7 years of HCQ use and was 
approximately 5 times greater after 7 years of usage (16). 
In another study of 2,361 patients who used HCQ 
continuously for at least 5 years, the overall prevalence 
of HCQ-induced retinopathy was 7.5% (17). The pattern 
and prevalence of HCQ-induced retinal toxicity differs 
between Iranian patients and other Asian patients, 
especially during the early period of usage (18), 
potentially due to ethnic differences. 
A study by Qader et al on 60 Canadian patients who used 
HCQ showed that approximately 30% of the subjects 
showed abnormal retinal changes after 6 months. In 
addition, depressive changes appeared in 12 of the 
subjects (9). Furthermore, HCQ therapy significantly 
worsened the perimetric results in about 55% of the 
patients with abnormal anterior segments and 50.0% of 
subjects with abnormal posterior segments, compared 
with the findings at the time of enrollment (9). Further 
long-term large prospective studies involving different 
ethnic groups and highly sensitive and specific 
techniques for detecting early retinal changes are 
necessary to confirm the results of our study regarding 
the percentage of patients taking HCQ who develop 
retinal toxicity. Among the risk factors associated with 
retinal toxicity, the most important were the cumulative 
HCQ dose and duration of HCQ use. Previous research 
has suggested that the risk of retinal toxicity increases 
with an increase in the daily and cumulative HCQ doses 
and the duration of treatment (16, 17), but other 
research has indicated conflicting results regarding the 
association between daily HCQ dose and retinal toxicity 
(17). Our study indicated that there was no association 
with daily HCQ dose, though this may be due to the small 
sample size used . 
Previous research has shown that virtually all patients 
with retinal toxicity associated with HCQ are aged >40 
years (13). The results of our study are compatible with 
this finding. A possible explanation for the association 
between age and HCQ-induced retinal toxicity is that 
younger individuals have significant neuronal reserves 
that prevent the development of retinal toxicity for many 
years (13). We observed that patients with SLE, RA, or 
other rheumatic diseases did not have different risks of 
retinal toxicity. Although the exact mechanism of retinal 
toxicity is unknown, it is likely that it is not related to 
autoimmunity. Previous studies have identified that the 
HCQ-induced damage involves outer retinal structures, 
retinal ganglion cells, the inner plexiform layer, and the 
retinal nerve fiber layer (18-21). 
In conclusion, the percentage of patients with HCQ-
induced retinal toxicity was high (30.5%). The risk factors 
were advanced age, a high cumulative HCQ dose, and a 
longer duration of HCQ use. Large multicenter studies 
using modern techniques are required to confirm the 
results of this study and to identify further risk factors. 
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